Molecular geometry and adrenergic drug activity.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001679:Biogenic Amines / Q000378:metabolism; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D002395:Catecholamines / Q000096:biosynthesis; D055598:Chemical Phenomena; D002621:Chemistry; D003593:Cytoplasm / Q000378:metabolism; D003864:Depression, Chemical; D004296:Dopa Decarboxylase / Q000378:metabolism; D004299:Dopamine beta-Hydroxylase / Q000378:metabolism; D007536:Isomerism; D008968:Molecular Conformation; D008995:Monoamine Oxidase / Q000378:metabolism; D009451:Neuroeffector Junction / Q000187:drug effects; D009474:Neurons / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000302:isolation & purification; D010636:Phenols / Q000494:pharmacology; D010625:Phenylethanolamine N-Methyltransferase / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000187:drug effects*; D013565:Sympatholytics / Q000494:pharmacology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D001679:Biogenic Amines; D002395:Catecholamines; D004364:Pharmaceutical Preparations; D010636:Phenols; D013565:Sympatholytics; D014446:Tyrosine 3-Monooxygenase; D004299:Dopamine beta-Hydroxylase; D008995:Monoamine Oxidase; D010625:Phenylethanolamine N-Methyltransferase; D002394:Catechol O-Methyltransferase; D004296:Dopa Decarboxylase